DrugPatentWatch Database Preview
Drugs in Development Information for CC-220
What is the drug development status for CC-220?
CC-220 is an investigational drug.
There have been 10 clinical trials for CC-220.
The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2014.
The most common disease conditions in clinical trials are Lupus Erythematosus, Systemic, Liver Diseases, and Neoplasms, Plasma Cell. The leading clinical trial sponsors are Celgene Corporation, Celgene, and [disabled in preview].
There are twenty-five US patents protecting this investigational drug and two hundred and thirty-five international patents.
Summary for CC-220
| US Patents | 25 |
| International Patents | 235 |
| US Patent Applications | 55 |
| WIPO Patent Applications | 34 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2014-09-01) |
| Vendors | 20 |
Recent Clinical Trials for CC-220
| Title | Sponsor | Phase |
|---|---|---|
| Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects | Celgene | Phase 1 |
| Radiolabeled Study of CC-220 in Healthy Male Subjects | Celgene | Phase 1 |
| A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus | Celgene | Phase 2 |
Clinical Trial Summary for CC-220
Top disease conditions for CC-220
Top clinical trial sponsors for CC-220
US Patents for CC-220
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| CC-220 | Start Trial | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | Celgene Corporation (Summit, NJ) | Start Trial |
| CC-220 | Start Trial | Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin- e-2,6-dione | Celgene Corporation (Summit, NJ) | Start Trial |
| CC-220 | Start Trial | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast | Celgene Corporation (Summit, NJ) | Start Trial |
| CC-220 | Start Trial | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CELGENE CORPORATION (Summit, NJ) | Start Trial |
| CC-220 | Start Trial | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | Celgene Corporation (Summit, NJ) | Start Trial |
| CC-220 | Start Trial | 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-- dione for the treatment of systemic lupus erythematosus | Celgene Corporation (Summit, NJ) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CC-220
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| CC-220 | Australia | 2015305449 | 2034-08-22 | Start Trial |
| CC-220 | Brazil | 112017003620 | 2034-08-22 | Start Trial |
| CC-220 | Canada | 2958867 | 2034-08-22 | Start Trial |
| CC-220 | Chile | 2017000416 | 2034-08-22 | Start Trial |
| CC-220 | China | 107073115 | 2034-08-22 | Start Trial |
| CC-220 | Eurasian Patent Organization | 201790439 | 2034-08-22 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
